Abstract
136 untreated multiple myeloma patients of stage II and III were collected in the study. 37/51 stage II patients had progressive disease and were treated with melphalan and prednisone (MP). 85 patients were of stage III and randomized into MP and vincristine, BCNU, adriamycin, melphalan and dexamethasone (VBAMDex) treatment groups. 55% of MP treated patients responded versus 75% of the VBAMDex group. Since the study has been activated only 16 months ago, no difference in survival could be observed.
Publication types
-
Clinical Trial
-
Comparative Study
-
Multicenter Study
-
Randomized Controlled Trial
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Carmustine / administration & dosage
-
Dexamethasone / administration & dosage
-
Doxorubicin / administration & dosage
-
Female
-
Follow-Up Studies
-
Humans
-
Male
-
Melphalan / administration & dosage
-
Multicenter Studies as Topic
-
Multiple Myeloma / drug therapy*
-
Multiple Myeloma / pathology
-
Neoplasm Staging
-
Prednisone / administration & dosage
-
Vincristine / administration & dosage
Substances
-
Vincristine
-
Dexamethasone
-
Doxorubicin
-
Melphalan
-
Carmustine
-
Prednisone